The HAELO trial will assess the therapy’s safety and efficacy in 60 adult subjects with Type I or Type II HAE.

NEW YORK CITY, NY / ACCESS Newswire / January 22, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims ...

Technical analysis for Intellia Therapeutics Inc. NTLA including support levels resistance levels and stop losses for NTLA ...

Intellia Therapeutics NTLA announced that it has dosed the first patient in the phase III HAELO study evaluating NTLA-2002, its novel in vivo CRISPR gene editing therapy for the treatment of ...

Intellia Therapeutics (NTLA) announced the first patient has been dosed in the global Phase 3 study of NTLA-2002 for the treatment of ...

A look at Intellia Therapeutics, Inc. and Editas Medicine, Inc., including their restructuring and pipeline prioritization.

NTLA stock falls more than 21% in a week after the company announced strategic priorities and key anticipated milestones for 2025. We advise prospective investors to stay on the sidelines for now.

Intellia Therapeutics Inc (NTLA) stock saw a modest uptick, ending the day at $9.5 which represents a slight increase of $0.08 or 0.85% from the prior close of $9.42. The stock opened at $9.48 and ...

Hennion & Walsh Asset Management Inc. lifted its holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA – Free Report) by 125.2 ...

Intellia Therapeutics, Inc. (NASDAQ:NTLA) shares acquire momentum first thing. The Cambridge, Mass.-based Intellia, a leading clinical-stage gene editing company focused on revolutionizing medicine ...

Intellia Therapeutics Inc (NTLA) stock saw a decline, ending the day at $9.42 which represents a decrease of $-0.29 or -2.99% from the prior close of $9.71. The stock opened at $9.76 and touched a low ...

NEW YORK, NY / ACCESS Newswire / January 22, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Intellia Therapeutics, Inc. ("Intellia" or the "Company") (NASDAQ:NTLA). Such ...